Safety and Efficacy of Nilotinib vs. Imatinib in the Treatment of Newly Diagnosed Chinese Ph+ CML-CP Patients

Status:
Completed

Trial end date:
2014-10-01

Target enrollment:

Participant gender:

The study will compare the efficacy and safety of Nilotinib versus Imatinib in newly diagnosed Chinese patients with CML-CP.

Phase 3

Novartis Pharmaceuticals

Imatinib Mesylate